This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revision | Last revisionBoth sides next revision | ||
home:pathogenesis:vitamind:longterm [05.26.2019] – [Immunosuppression and insufficient followup in vitamin D studies] sallieq | home:pathogenesis:vitamind:longterm [06.11.2019] – [Also] sallieq | ||
---|---|---|---|
Line 76: | Line 76: | ||
- | [[https:// | + | view [[https:// |
+ | |||
+ | ===== Furthermore ===== | ||
+ | |||
+ | Two recent publications challenge the belief that 25(OH)D levels greater than 30 ng/mL are optimal for bone health. In a randomized, placebo-controlled trial, high-dose, once-yearly vitamin D therapy increased the incidence of fractures and falls. The second study reported that high-dose vitamin D did not reduce levels of parathyroid hormone or bone resorption among adults with 25(OH)D levels less than 32 ng/mL at baseline. It is time to question whether serum 25(OH)D levels of 30 ng/mL or greater are necessary for all individuals. (({{pubmed> | ||
+ | |||
+ | |||
+ | |||
+ | Blood vitamin D levels were associated with a risk of metabolic syndrome in cross-sectional studies but not in longitudinal studies. (({{pubmed> | ||
+ | |||
+ | Evidence does not support the use of vitamin D supplementation for the prevention of cancer, respiratory infections or rheumatoid arthritis. Similarly, evidence does not support vitamin D supplementation for the treatment of multiple sclerosis and rheumatoid arthritis or for improving depression/ | ||
+ | |||
+ | New evidence indicates that both high and low 25(OH)D levels may be associated with increased health risks.(({{pubmed> | ||
+ | |||
+ | Despite a few hundred systematic reviews and meta-analyses, | ||
+ | |||
+ | |||
+ | |||